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Association of Lower Extremity Performance With Cardiovascular and
All-Cause Mortality in Patients With Peripheral Artery Disease:
A Systematic Review and Meta-Analysis
Dylan R. Morris; Alexander J. Rodriguez, BMedSci (Hons); Joseph V. Moxon, PhD; Margaret A. Cunningham, PhD;
Mary M. McDermott, MD; Jonathan Myers, PhD; Nicholas J. Leeper, MD; Rhondda E. Jones, PhD; Jonathan Golledge, MChir
Background-—Peripheral artery disease (PAD) is associated with impaired mobility and a high rate of mortality. The aim of this
systematic review was to investigate whether reduced lower extremity performance was associated with an increased incidence of
cardiovascular and all-cause mortality in people with PAD.
Methods and Results-—A systematic search of the MEDLINE, EMBASE, SCOPUS, Web of Science, and Cochrane Library databases
was conducted. Studies assessing the association between measures of lower extremity performance and cardiovascular or all-
cause mortality in PAD patients were included. A meta-analysis was conducted combining data from commonly assessed
performance tests. The 10 identiﬁed studies assessed lower extremity performance by strength tests, treadmill walking
performance, 6-minute walk, walking velocity, and walking impairment questionnaire (WIQ). A meta-analysis revealed that shorter
maximum walking distance was associated with increased 5-year cardiovascular (unadjusted RR=2.54, 95% CI 1.86 to 3.47,
P<105, n=1577, ﬁxed effects) and all-cause mortality (unadjusted RR=2.23 95% CI 1.85 to 2.69, P<105, n=1710, ﬁxed effects).
Slower 4-metre walking velocity, a lower WIQ stair-climbing score, and poor hip extension, knee ﬂexion, and plantar ﬂexion
strength were also associated with increased mortality. No signiﬁcant associations were found for hip ﬂexion strength, WIQ
distance score, or WIQ speed score with mortality.
Conclusions-—A number of lower extremity performance measures are prognostic markers for mortality in PAD and may be useful
clinical tools for identifying patients at higher risk of death. Further studies are needed to determine whether interventions that
improve measures of lower extremity performance reduce mortality. ( J Am Heart Assoc. 2014;3:e001105 doi: 10.1161/
JAHA.114.001105)
Key Words: lower extremity performance • mortality • peripheral artery disease
P eripheral artery disease (PAD) is an athero-occlusivedisease of the lower limb arterial tree and is a common cause of morbidity and mortality in Western countries. World-wide, it is estimated that over 200million people are affected by
PAD.1 Approximately one third of these individuals experience
intermittent claudication and subsequent impairment of mobil-
ity.2 PAD patients demonstrate impaired performance on a
range of lower extremity performance tests including poorer
walking endurance, slower walking velocity, and reduced lower
limb strength associated with impaired health-related quality of
life.3,4 Randomized controlled trials suggest that exercise
therapies aimed at improving lower extremity performance,
including supervised exercise programs, home-based walking
interventions, and resistance training improve lower limb
symptoms and quality of life among PAD patients.5,6
Observational studies demonstrate that PAD presence is a
strong independent predictor of coronary and cerebrovascular
events.7 Even with current best medical therapy, the risk of
cardiovascular and all-cause mortality remains 3 times
higher in PAD patients compared to those without PAD.7 More
effective interventions for PAD management are required to
reduce cardiovascular and all-cause mortality among this
From the Vascular Biology Unit, Queensland Research Centre for Peripheral
Vascular Disease, School of Medicine and Dentistry (D.R.M., A.J.R., J.V.M., J.G.)
and Faculty of Medicine, Health and Molecular Sciences (R.E.J.), James Cook
University, Townsville, Australia; Psychology Department, University of Stirling,
Stirling, United Kingdom (M.A.C.); Feinberg School of Medicine, Northwestern
University, Chicago, IL, USA (M.M.M.); Division of Cardiovascular Medicine,
Department of Medicine, Veterans Affairs Palo Alto Health Care System, Stanford
University, Stanford, CA (J.M.); Division of Vascular Surgery, Stanford University
School of Medicine, Stanford, CA (N.J.L.); Department of Vascular and
Endovascular Surgery, The Townsville Hospital, Townsville, Australia (J.G.).
Correspondence to: Jonathan Golledge, MChir, Queensland Research Centre
for Peripheral Vascular Disease, School of Medicine and Dentistry, James
Cook University, Queensland, Australia 4811. E-mail: jonathan.golledge@jcu.
edu.au
Received May 17, 2014; accepted July 14, 2014.
ª 2014 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.114.001105 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on September 29, 2014http://jaha.ahajournals.org/Downloaded from 
high-risk population. It is suggested, although unproven, that
interventions that improve lower extremity performance may
reduce cardiovascular risk among PAD patients.8 If true, this
would provide a rationale for interventions, such as exercise
therapy, beyond the beneﬁt they provide in reducing symp-
toms. Currently no randomized trials have examined the effect
of such interventions on long-term cardiovascular risk;
however, a number of observational studies have assessed
the association between lower extremity performance mea-
sures and cardiovascular and all-cause mortality. We con-
ducted a systematic review and meta-analysis to summarize
current evidence for the association between lower extremity
performance measures and mortality in PAD patients.
Methods
Literature Search
This systematic review was performed according to the
Preferred Reporting Items of Systematic Reviews and Meta-
Analyses (PRISMA) statement and the Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) guidelines.9,10
A literature search was conducted to identify studies investi-
gating the association between measurements of lower
extremity performance and mortality in patients with PAD.
TheMEDLINE (1966), EMBASE (1980), SCOPUS (1996), Web of
Science (1965), and Cochrane Library databases (1992) were
searched from inception to March 16, 2014 with no language
restrictions. The following search terms were applied: (Periph-
eral artery disease OR Peripheral arterial disease OR PAD OR
Claudication OR limb ischaemia OR limb ischemia)[Title] AND
(Muscle OR Walk* OR Strength OR Exercise OR Treadmill OR
Physical activity)[Title/Abstract] AND (Mortality OR Death OR
Outcome OR Prognos*)[Title]. Titles and abstracts were
screened by 1 author (D.R.M.) to identify potentially relevant
studies. If the suitability of an article was uncertain, the full text
was assessed. All potentially eligible studies were subse-
quently evaluated in detail by 1 reviewer (D.R.M.) through
consideration of the full text. Inclusion required assessment of
a lower extremity performance measure in PAD patients, and
analysis for association with either cardiovascular mortality or
all-cause mortality on follow-up. Studies were excluded if the
cohort was deﬁned by the presence of PAD and an additional
confounding disease process (eg, chronic renal failure), if the
cohort underwent a revascularization procedure as part of the
study, or if PAD speciﬁc results could not be distinguished from
those of a larger population consisting of individuals without
PAD. Studies investigating the association between physical
activity during daily life and mortality were not considered
eligible. Physical activity was deﬁned as any bodily movement
produced by skeletal muscles that results in energy expendi-
ture, and may be inﬂuenced by factors other than lower
extremity performance.11 Database searches were supple-
mented by hand searching the reference lists of included
studies and utilizing the related articles function in PubMed.
Data Extraction
Two investigators (D.R.M., A.J.R.) extracted data using a
predeﬁned form. All data were cross-checked in a consensus
meeting and discrepancies were resolved through discussion.
Data extracted included the sample size, number of cardio-
vascular and all-cause deaths, length of follow-up, baseline
demographic information, characteristics of the study popu-
lation, method of diagnosis of PAD, detailed descriptions of
the lower extremity performance tests, adjustment factors,
and primary results. In addition, we recorded the number of
participants in each group and estimated the corresponding
5-year mortality rate from Kaplan–Meier survival curves.
Authors of eligible studies were contacted where additional
information was required, all of whom replied.
Quality Assessment
Methodological quality and potential bias of included studies
were assessed by 2 investigators (D.R.M., A.J.R.). A quality
assessment form was devised using elements of the Newcas-
tle Ottawa scale and Cochrane collaboration tool for assessing
risk of bias.12,13 Quality measures included (1) whether data
were collected prospectively or retrospectively; (2) description
of the inclusion and exclusion criteria for PAD participants;
(3) assessment of PAD severity at baseline (according to
ankle–brachial index [ABI] or angiographic scoring); (4)
reporting of vascular risk factors at baseline; (5) follow-up
time (mean or median ≥4 years); (6) comprehensive mortality
assessment (either searched Social Security death register or
contacted proxies of study participants); (7) percentage of the
cohort analyzed at follow-up (≥90% considered acceptable);
and (8) results adjusted for multiple confounding variables
(age, sex, and ≥2 vascular risk factors). We did not exclude
any studies due to poor methodological quality.
Statistical Analysis
Meta-analyses were performed for lower extremity perfor-
mance measures that were evaluated in at least 3 separate
cohort studies. Both unadjusted and maximally adjusted risk
ratios (RR) comparing the highest with the lowest-perfor-
mance quantiles were combined using ﬁxed-effects and
random-effects models. Unadjusted RRs for cardiovascular
and all-cause mortality were derived from Kaplan–Meier
survival curves at 5 years follow-up as described by Parmar
et al14 Maximally adjusted RRs calculated using Cox
proportional-hazards analysis were transcribed directly from
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published data tables. The Cochrane Q statistic and I2 index
were used to assess the degree of heterogeneity across
studies.12 I2 values of >50% were accepted to denote
statistical heterogeneity. Sensitivity analyses were con-
ducted using the one--study-remove approach to assess
the impact of each study on the combined effect.12 Funnel
plots of the effect size versus the standard error of the log-
transformed effect were constructed to assess potential
publication bias. Statistical tests were considered signiﬁcant
if the 2-sided P value was less than 0.05. All computations
were performed using RevMan Version 5.2 (Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2012).
Results
Study Selection
Initial database searches yielded 117 potentially eligible
studies after removal of duplicates (Figure 1). A total of 105
articles were excluded based on review of their titles and
abstracts. The most common reasons for exclusion were
absence of a lower extremity performance measure and
failure to investigate cardiovascular or all-cause mortality.
After evaluating 12 full-text studies, a further 2 were
excluded because they investigated clinic-referred patients
without a deﬁnitive diagnosis (de Liefde et al), or did not
investigate the association of walking capacity with mortality
(Wilson et al).15,16 No additional studies were identiﬁed from
hand searching the reference lists of included studies;
therefore, 10 studies were included in this review
(Table 1).8,17–25
Study Characteristics
The sample size of included studies ranged from 118 to 1624
participants, with a median sample size of 441 participants.
Eight of the 10 studies were conducted in the United States;
the remaining 2 were conducted in Japan and the Nether-
lands.23,25 All studies were hospital-based and recruited
either vascular inpatients or individuals presenting to a
vascular clinic or noninvasive vascular laboratory. Eight of
the 10 studies comprised patients with both symptomatic and
asymptomatic PAD; however, 2 studies only assessed
Figure 1. Outline of the study. One hundred and seventeen published studies assessing the association
of lower extremity performance measures with mortality in peripheral artery disease (PAD) patients were
identiﬁed by searching the EMBASE, MEDLINE, SCOPUS, Web of Science, and Cochrane Library databases.
Appraisal of the abstracts identiﬁed 12 studies eligible for full-text appraisal. From these, a further 2 articles
were excluded, yielding a total of 10 studies included in the review.
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patients with intermittent claudication.17,23 An ABI <0.90 was
used as the diagnostic inclusion criterion for PAD in all but 1
study.19 Baseline mean ABI ranged from 0.63 to 0.67. Follow-
up ranged from an average of 3.7 to 11.3 years. All studies
provided detailed baseline clinical and demographic data
(Table 2).
The methodological quality of included studies is shown in
Table 3. Nine studies were conducted prospectively and 1
study was performed retrospectively.17 Inclusion and exclusion
criteria were clear in all but 1 study.19 Nine of the 10 studies
had an average follow-up of ≥4 years, which was considered
sufﬁcient to detect clinically relevant differences in mortality.20
Mortality was determined either through searching Social
Security death registers (n=3), contacting proxies of study
participants (n=1), or both (n=6). All of the prospective studies
included ≥90% of baseline participants in their ﬁnal analysis.
Eight of the 10 studies adjusted their results for age, sex, and at
least 2 vascular risk factors.8,18,20–25
Investigators examined a range of lower extremity perfor-
mance measures that can be grouped into 3 general
categories: (1) lower limb strength tests, (2) objectively
measured walking performance, and (3) the walking impair-
ment questionnaire (WIQ). A summary of ﬁndings is presented
in Table 4.
Lower Limb Strength
Singh et al (N=410) and McDermott et al (N=434) assessed
the association of lower extremity performance and mortality
by a range of strength tests, including isometric hip ﬂexion,
hip extension, knee ﬂexion, knee extension, plantar ﬂexion,
and knee extension power.21,24 Both studies were conducted
on 2 related cohorts (WALCS I and WALCS II, respectively)
recruited from Chicago, with results adjusted for age, sex,
race, body mass index, ABI, smoking, and comorbidities.21,24
Poor isometric strength for hip extension, knee ﬂexion, knee
extension power, and plantar ﬂexion were independently
associated with increased cardiovascular and all-cause mor-
tality in both studies.21,24 Conversely, no signiﬁcant associ-
ations were found for hip ﬂexion strength, which was
investigated by Singh et al only.24 Knee extension strength
was not associated with mortality in the total sample of
Table 1. Studies Assessing the Association of Lower Extremity Performance Measures and Mortality in Patients With Peripheral
Artery Disease
Study Year Country NPAD ABI Claudicants Follow-Up (y)
NAC
Mortality
NCV
Mortality* Assessment of Lower Extremity Performance
Jain et al8 2013 USA 442 — — 4.71 (2.26
to 6.24)†
123 45 2-y decline in WIQ distance, speed,
and stair-climbing scores
Leeper et al19 2013 USA 725 — 68.4% 11.36.3‡ 364 132 Customized symptom limited ramp
treadmill protocol
Jain et al18 2012 USA 638 0.650.15‡ 32.0% 4.5† 221 78 WIQ distance, speed, and stair-
climbing scores
McDermott
et al21
2012 USA 434 0.630.2‡ — 4.01.3‡ 103 35 Knee extension strength, knee
extension power, and plantar
flexion
McDermott
et al20
2011 USA 440 0.660.15‡ — 3.71 (2.17
to 6.08)†
102 39 Decline in 6-min walk, fast-paced,
and usual- paced 4-metre walking
velocity
Singh et al24 2010 USA 410 — — 5.01.9‡ 126 41 Isometric hip extension, hip flexion,
knee extension, and knee flexion
de Liefde
et al25
2009 Netherlands 1624 0.670.20‡ — 5.0‡ 552 309 Treadmill total walking distance at
4 km/h
Sakamato
et al23
2009 Japan 118 0.540.18‡ 100.0% 5.73.9‡ 33 16 Maximum walking distance; details
not described
Gardner et al17 2008 USA 434 — 100.0% 5.1† 108 — 6-min walk, WIQ distance, speed,
and stair-climbing scores
McDermott
et al22
2008 USA 444 0.65‡ — 4.81 (3.13
to 5.17)†
127 55 6-min walk, fast-paced and usual-
paced 4-metre walking velocity
ABI indicates ankle-brachial pressure index; AC, all-cause; CV, cardiovascular; N, number; PAD, peripheral artery disease; WIQ, walking impairment questionnaire; y, years.
*Deﬁned as death from coronary heart disease, stroke, peripheral vascular disease, and other cardiovascular disease in 8 studies. Deﬁned as death from cardiac causes in 1 study.25
†Median and interquartile range. In some cases interquartile range was not provided.
‡Mean and standard deviation. In one case standard deviation was not provided.
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participants; however, Singh et al found a signiﬁcant associ-
ation between knee extension strength and all-cause mortality
in males (P=0.010) following subgroup analysis.24
Objectively Measured Walking Performance
Walking ability was assessed as a potential prognostic marker
for mortality in 5 studies.17,19,22,23,25 Two studies used the
6-minute walk test whereby patients were instructed to cover
as much distance as possible along a corridor within
6 minutes.17,22 Poor performance on the 6-minute walk test
was associated with increased rates of cardiovascular
(P<0.001) and all-cause mortality (P=0.001) in 1 study but
was not signiﬁcantly associated with higher all-cause mortal-
ity (P=0.077) in a second study.17,22 An important difference
between these studies is that Gardner et al adjusted their
results for the WIQ distance score, which is closely correlated
with the 6-minute walk test.17,26 This adjustment was not
included by McDermott et al, and this may account for the
conﬂicting ﬁndings.22 Three studies assessed maximum
walking distance using symptom-limited ramp treadmill
protocols, and all reported poor performance to be signiﬁ-
cantly associated with higher rates of cardiovascular and
all-cause mortality (Table 4).19,23,25
A meta-analysis of 3 studies for the association between
maximum walking distance and 5-year mortality is shown in
Figure 2. Combined results represent a composite of treadmill
walking tests and the 6-minute walk test. Shorter walking
distance was signiﬁcantly associated with increased risk
of cardiovascular (unadjusted RR =2.54; 95% CI 1.86 to 3.47;
P<105, n=1577) and all-cause mortality (unadjusted
RR =2.23; 95% CI 1.85 to 2.69; P<105, n=1710) under a
ﬁxed-effects model. Random-effects meta-analysis demon-
strated similar effect estimates for both cardiovascular
(unadjusted RR =2.64; 95% CI 1.76 to 3.96; P<104) and
all-cause mortality (unadjusted risk ratios=2.23; 95% CI 1.85
to 2.69; P<104). Two of the 3 studies included in the analysis
were considered high quality (Table 3); however, 1 study used
a sample recruited from US military veterans and may not be
representative of the more general PAD population.19 Heter-
ogeneity between studies was not considered signiﬁcant
(cardiovascular mortality: I2=31%; all-cause mortality: I2=0%),
although the potential for publication bias could not be
gauged due to the small number of included studies.
Sensitivity analyses demonstrated that the association
remained signiﬁcant after removal of any 1 study (Tables 5
and 6). Meta-analysis of maximally adjusted RRs yielded more
conservative effect estimates but with greater heterogeneity
(Figure 3). Included studies adjusted their RRs for a range of
different covariates, potentially introducing bias into the
summary-effect estimates (Table 4). Data from Gardner et al
and Sakamoto et al were not included in the meta-analysisTa
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because published RRs had very narrow conﬁdence intervals
that would not have been expected from the sample sizes
included in the studies (Table 4).17,23 Meta-analysis could not
be performed for speciﬁc walking endurance tests because
fewer than 3 published studies evaluated each test.
Walking velocity was investigated in 2 studies from the
same cohort.20,22 Slower fast-paced 4-metre (4-m) walking
velocity was signiﬁcantly associated with cardiovascular and
all-cause mortality, whereas slower normal-paced 4-m
walking velocity was only associated with all-cause mortal-
ity.22 Patients with the greatest decline in the 6-minute walk
test and fast-paced 4-m velocity test over 2 years had
signiﬁcantly increased risk of subsequent cardiovascular and
all-cause mortality.20
Walking Impairment Questionnaire
Jain et al and Gardner et al assessed the association of lower
WIQ scores with mortality in 638 and 434 PAD patients,
respectively.17,18 The WIQ is a subjective measure of patient-
perceived walking performance developed for individuals with
PAD. Both Jain et al and Gardner et al reported an association
between lower WIQ stair-climbing score with increased
mortality (Table 4).17,18 Conversely, no associations were
found for the WIQ distance score or speed score in either
study. An additional study by Jain et al, conducted on the
same patient cohort, showed that a signiﬁcant decline in WIQ
stair-climbing score, distance score, and speed score over
2 years were each associated with increased all-cause
mortality.8
Discussion
The main ﬁnding of this systematic review was that shorter
walking distance in a 6-minute walk test or a treadmill test
was associated with an increased risk of cardiovascular and
all-cause mortality among people with PAD. These ﬁndings
were conﬁrmed in a meta-analysis that demonstrated PAD
patients in the lowest performance quantile for walking
endurance had more than twice the risk of cardiovascular and
all-cause mortality compared to those in the highest quantile.
Moreover, this risk remained signiﬁcant, although not as
strong, after some studies adjusted for a range of traditional
cardiovascular risk factors. Although it is well established that
ambulation and survival are closely correlated in the general
population, this association had not been conﬁrmed in PAD
patients.27 Summary risk estimates generated in the present
meta-analysis were similar to those seen in the general
population who completed a long-distance corridor walk test,
suggesting that even among patients with advanced walking
impairment, limited ambulation predicts mortality.27
The association between lower limb strength and mortality
was variable, as evidenced by conﬂicting ﬁndings in the
literature.21,24 Poorer hip extension strength, knee ﬂexion
strength, plantar ﬂexion strength, and knee extension power
were associated with increased cardiovascular and all-cause
mortality. In contrast, poorer hip ﬂexion and knee extension
strength were not consistently associated with mortality.
Reasons for these differences are unclear. One possible
explanation is that some lower limb muscle groups may be
more susceptible to muscle ischemia than others, and conse-
Table 3. Quality Assessment of Included Studies
Study
Prospective
Data
Collection
Description
of Selection
Criteria
Assessment
of Baseline
PAD Severity
Detailed
Population
Characteristics
Follow-
Up
≥4 Years
≥90% of
Participants
Included in Final
Analysis
Comprehensive
Mortality
Assessment*
Adjustment
for
Population
Stratiﬁcation
Jain et al8 Yes Yes Yes Yes Yes Yes Yes Yes
Leeper et al19 Yes No No Yes Yes Yes Yes No
Jain et al18 Yes Yes Yes Yes Yes Yes Yes Yes
McDermott
et al21
Yes Yes Yes Yes Yes Yes Yes Yes
McDermott
et al20
Yes Yes Yes Yes No Yes Yes Yes
Singh et al24 Yes Yes Yes Yes Yes Yes Yes Yes
de Liefde et al25 Yes Yes Yes Yes Yes Yes Yes Yes
Sakamato et al23 Yes Yes Yes Yes Yes Yes Yes Yes
Gardner et al17 No Yes Yes Yes Yes N/A Yes No
McDermott
et al22
Yes Yes Yes Yes Yes Yes Yes Yes
N/A indicates not applicable due to retrospective study design; PAD, peripheral artery disease.
*Considered comprehensive if mortality status was searched on a Social Security death register or if proxies of study participants were contacted.
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quently, more sensitive indicators of systemic atherosclerosis.
The prognostic value of lower limb strength has not been
studied extensively in the general population. However, hazard
ratios for lower limb strength reported in this systematic review
appear to be considerably higher than those for hand grip
strength in the general population, tentatively suggesting that
lower limb muscle strength provides greater prognostic infor-
mation in PAD patients than individuals without PAD.28
Figure 2. Meta-analysis of the association between maximum walking distance and 5-year cardiovascular
and all-cause mortality. Forest plot illustrating unadjusted risk ratios (RRs) and 95% CIs for the association of
shorter walking distance with cardiovascular and all-cause mortality. The diamond represents an overall RR
calculated in the current meta-analysis. The number n represents the sum of patients in the highest and
lowest quantiles for each study. P<105 under both ﬁxed-effects and random-effects models. *Comparison of
lowest- performance quartile to highest-performance quartile.22,25 †Comparison of patients with performance
below set value compared to patients with performance above and including set value.19
Table 5. Fixed-Effects Leave-one-Out Sensitivity Analyses for the Association Between Maximum Walking Distance and Mortality
Study Removed
Meta-Analysis of Unadjusted Data Meta-Analysis of Adjusted Data
RR, 95% CI P Value RR, 95% CI P Value
Cardiovascular mortality
de Liefde et al25 2.80 (1.77 to 4.44) <104 1.67 (1.08 to 2.58) <104
Leeper et al19 2.64 (1.77 to 3.95) <105 2.00 (1.34 to 2.99) 7 9 104
McDermott et al22 2.36 (1.71 to 3.26) <105 1.95 (1.38 to 2.74) 104
All-cause mortality
de Liefde et al25 2.48 (1.92 to 3.21) <105 2.42 (1.81 to 3.23) <105
Leeper et al19 2.04 (1.62 to 2.57) <105 1.84 (1.38 to 2.45) <104
McDermott et al22 2.23 (1.81 to 2.74) <105 2.03 (1.61 to 2.57) <105
RR indicates risk ratio.
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Participant self-report of stair-climbing ability was also
associated with mortality in 2 separate studies.17,18 Objec-
tively measured stair-climbing ability has been shown to be a
reliable substitute for peak oxygen consumption in the
general population and may explain why the WIQ stair-
climbing score, as opposed to the WIQ distance or speed
Table 6. Random Effects Leave-one-Out Sensitivity Analyses for the Association Between MaximumWalking Distance and Mortality
Study Removed
Meta-Analysis of Unadjusted Data Meta-Analysis of Adjusted Data
RR, 95% CI P Value RR, 95% CI P Value
Cardiovascular mortality
de Liefde et al25 3.50 (1.31 to 9.38) 0.01 3.30 (1.56 to 6.98) 0.002
Leeper et al19 3.44 (1.26 to 9.42) 0.02 2.77 (0.86 to 8.93) 0.09
McDermott et al22 2.36 (1.71 to 3.26) <105 1.96 (1.33 to 2.90) 6 9 104
All-cause mortality
de Liefde et al25 2.48 (1.92 to 3.21) <105 2.42 (1.81 to 3.23) <105
Leeper et al19 2.04 (1.62 to 2.57) <105 1.84 (1.38 to 2.45) <104
McDermott et al22 2.25 (1.70 to 2.98) <105 2.03 (1.42 to 2.91) 104
RR indicates risk ratio.
Figure 3. Meta-analysis of maximally adjusted risk ratios (RRs) for the association between maximum
walking distance and mortality in peripheral artery disease. Forest plot illustrating maximally adjusted RRs
and 95% CIs for the association of shorter walking distance with cardiovascular and all-cause mortality.
Covariates included in multivariate analyses for individual studies are listed in Table 4. The diamond
represents an overall RR calculated in the current meta-analysis. The number n represents the combined
sum of patients in each study. *P value calculated according to ﬁxed-effects model. †P value calculated
according to random-effects model.
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scores, was associated with mortality.29 Alternatively, it may
be possible that patients have more accurate recall of their
stair-climbing capacity because it is potentially easier to
quantify than walking distance and speed. The ﬁndings of this
review for the WIQ differ from that of the general population.
Nead et al found that the WIQ distance, speed, and stair-
climbing categories independently predicted cardiovascular
and all-cause mortality in a large cohort with normal ABI.30
Moreover, WIQ stair climbing appeared to be the weakest
predictor of mortality of all 3 WIQ categories. Further studies
are required to reconcile these inconsistencies.
Several possible explanations exist for the association
between reduced lower extremity performance and mortality
in PAD patients. First, individuals with PAD suffer multiple
comorbidities that may limit mobility and reduce survival. Two
of the three studies included in our meta-analysis of adjusted
RRs (Figure 3) thoroughly adjusted their results for confound-
ing chronic diseases. As expected, adjusted RRs were not as
strongly associated with mortality as unadjusted RRs, and we
cannot exclude the possibility that the association between
walking distance and mortality would not exist after compre-
hensive, uniform adjustment of comorbid conditions. Sec-
ondly, the lower extremity performance measures we
investigated may possibly reﬂect the degree of peripheral
atherosclerosis. Several of these performance measures have
previously been shown to be associated with ABI, which is a
marker of systemic atherosclerosis and cardiovascular
risk.4,7,31 Two of the three studies included in our maximally
adjusted risk estimates for cardiovascular and all-cause
mortality adjusted their results for ABI. Finally, there is some
evidence to suggest that skeletal muscle itself has functional
roles that may act to reduce cardiovascular risk. Preclinical
studies demonstrate that healthy skeletal muscle secretes an
array of anti-inﬂammatory and cardioprotective cytokines.32 It
is possible that the association between poor lower extremity
performance and mortality is in part mediated by loss of
healthy skeletal muscle, which has beneﬁcial anti-inﬂamma-
tory or other effects.33 Further work is required to explore
these hypotheses.
This review supports the use of corridor-walking tests,
such as the 6-minute walk, for patients with PAD. These tests
can feasibly be applied in the clinical setting to identify
individuals at high risk of cardiovascular events. In compar-
ison with other prognostic tests, the corridor-walking tests are
relatively inexpensive, do not require special equipment, and
can be undertaken efﬁciently by members of the nursing and
allied health teams. There are few other physical or biological
markers that have been shown to have comparable mortality
prediction in PAD patients. The ABI has previously been used
for cardiovascular risk prediction in PAD; however, 2 studies
in this review reported strong associations between walking
distance and mortality after adjusting for ABI. This suggests
that lower extremity performance measures provide prognos-
tic information beyond that of the ABI and comorbidities.
Overall, the ﬁndings of this review emphasize the importance
of measuring lower extremity performance in PAD patients
both in the clinical setting and in research studies. Further
investigation is needed to determine whether interventions
that improve walking ability, such as supervised exercise
programs, also reduce mortality.
This study has several limitations. First, data from individual
studies were observational and do not imply a causal associ-
ation. Interventional studies are required to elucidate whether
improvement in lower extremity performance prolongs life.
Second, there was variation in the methods used to assess
walking performance. Heterogeneity analyses were conducted
to assess interstudy variation and random-effects meta-
analysis was calculated for all comparisons, taking into account
interstudy variation. We were unable to investigate differences
in effect estimates across different walking tests due to the
limited number of studies available. Third, analyses conducted
to assess potential publication bias were underpowered, and
we cannot rule out the possibility that unpublished studies
exist. Finally, meta-analysis of maximally adjusted RRs incor-
porated both hazard ratios and RRs and combined data that
were adjusted for different and correlated confounders. We
cannot exclude the possibility that these associations no longer
exist after comprehensive, uniform adjustment. It is likely that
the results may have been inﬂuenced by residual confounding
that we could not adjust for.
In conclusion, this systematic review suggests that poorer
walking performance, assessed by the 6-minute walk or on a
treadmill, is associated with increased cardiovascular and all-
cause mortality in patients with PAD. These tests may provide
useful prognostic information for patients with PAD. Inter-
ventional trials are required to elucidate whether exercise
programs and other interventions that improve functional
performance reduce mortality in PAD patients.
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